Nuvectis Pharma Inc — Quarterly Financial Data (NASDAQ:NVCT) | MetaTrader

Open full chart

Financials

Overview Finanzbericht Statistics Dividends

Quarterly Annual

Dividends per share —0———0 — Dividend yield % —0———0 — Payout ratio % —0———0 —

Nachrichten

Nuvectis initiates phase 1b trial combining NXP900 with osimertinib

Nuvectis Pharma: H.C. Wainwright bestätigt "Buy"-Rating und sieht 72 % Kurspotenzial

Nuvectis Pharma stock rating reiterated at Buy by H.C. Wainwright

H.C. Wainwright bestätigt "Buy"-Rating für Nuvectis Pharma mit Kursziel von 10 US-Dollar

H.C. Wainwright reiterates Buy rating on Nuvectis Pharma stock at $10 target

Nuvectis Pharma adds former Intra-Cellular exec to board of directors

Nuvectis initiates phase 1b program for cancer drug NXP900

Nuvectis (NVCT) Q2 Loss Widens 43%

Nuvectis Pharma stock price target lowered to $10 at H.C. Wainwright

Nuvectis halts NXP800 development for ovarian cancer, shifts focus

Nuvectis reports positive drug interaction study for cancer drug NXP900

Friday’s Insider Activity: Top Buys and Sells in US Stocks